SHANGHAI, July 9, 2024 /PRNewswire/ -- Pulnovo Medical, a
globally recognized device pioneer in the treatment for pulmonary
hypertension and heart failure, has recently announced its
partnership with the Pulmonary Hypertension Association (PHA). This
partnership not only underscores Pulnovo Medical's growing global
influence but also empowers PHA's mission to extend and improve the
lives of those affected by pulmonary hypertension (PH)
worldwide.
Pulnovo Medical and the PHA are united by a collective vision to
a future where pulmonary hypertension is better understood and more
efficiently treated. Pulnovo Medical's PADN technology, an
innovative interventional therapy in the field of pulmonary
hypertension, provides a new and beneficial solution for patients
troubled by traditional drug treatments. Currently Pulnovo Medical
is conducting global trials in US and Europe. This strategic partnership aims to
combine Pulnovo Medical's cutting-edge PADN therapies for Pulmonary
Hypertension with PHA's extensive network to enhance public
awareness and improve the care of PH patients globally. As a member
of PHA, Pulnovo Medical will actively participate in PHA's
educational programs, research projects and advocacy campaigns. Our
collaboration will harness the urgency of our shared mission to
make a lasting impact on pulmonary hypertension patients
worldwide.
About PHA
The PHA was founded in 1991 in Florida and evolved into an international
community of more than 16,000 people with PH, caregivers, family
members and health care professionals. As one of the largest and
oldest pulmonary hypertension association in the world, the PHA
acts as a trusted liaison between the pulmonary hypertension
community and industry and academic partners.
About PADN
Pulmonary Artery Denervation (PADN) is a percutaneous pulmonary
artery intervention procedure that uses a PADN catheter to deliver
radiofrequency energy to the sympathetic nerves in the outer
membrane of the pulmonary artery, resulting in the disappearance of
the myelin sheath of the nerves and the fusion of the axons, which
inhibits sympathetic activity, increases cardiac output, reduces
pulmonary artery pressure, inhibits the pathologic remodeling of
the pulmonary arteries, improves the patient's exercise endurance
and cardiac function, and achieves long-term benefits from a single
minimally invasive procedure.
About Pulnovo Medical
Pulnovo Medical Limited, is a globally recognized device pioneer
in the treatment for pulmonary hypertension and heart failure, is
committed to leveraging our deep expertise in the science of
breakthrough technologies with the goal to market our innovative
therapeutic solutions and benefit patients around the world.
For more information, please visit: www.pulnovomed.us
View original
content:https://www.prnewswire.co.uk/news-releases/pulnovo-medical-announces-joining-phas-pulmonary-hypertension-association-corporate-committee-302191971.html